NextCure, Inc. (NASDAQ:NXTC) Short Interest Update

NextCure, Inc. (NASDAQ:NXTC) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 225,545 shares, an increase of 228.4% from the May 31st total of 68,687 shares. Based on an average daily volume of 217,601 shares, the days-to-cover ratio is presently 1.0 days. Approximately 7.1% of the shares of the company are sold short.

Analysts Set New Price Targets

NXTC has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a report on Monday, April 27th. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $23.00.

Institutional Trading of NextCure

A number of hedge funds have recently bought and sold shares of NXTC. Renaissance Technologies LLC grew its position in NextCure by 80.0% in the 1st quarter. Renaissance Technologies LLC now owns 60,534 shares of the company’s stock worth $647,000 after purchasing an additional 26,900 shares during the last quarter. Ikarian Capital LLC acquired a new position in shares of NextCure during the fourth quarter valued at about $3,382,000. Squadron Capital Management LLC acquired a new position in shares of NextCure during the fourth quarter valued at about $3,363,000. Millennium Management LLC bought a new stake in shares of NextCure in the fourth quarter valued at about $185,000. Finally, Boothbay Fund Management LLC bought a new stake in shares of NextCure in the fourth quarter valued at about $988,000. 42.65% of the stock is owned by institutional investors.

NextCure Stock Down 0.3%

NASDAQ NXTC traded down $0.01 during trading on Friday, hitting $1.65. The company’s stock had a trading volume of 64,326 shares, compared to its average volume of 171,077. The firm has a 50 day moving average price of $6.63 and a 200 day moving average price of $10.20. The firm has a market cap of $5.94 million, a P/E ratio of -0.10 and a beta of 1.30. NextCure has a 52 week low of $1.55 and a 52 week high of $15.74.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.10) by $0.23. On average, equities analysts expect that NextCure will post -7.9 earnings per share for the current year.

About NextCure

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.